Construction of orthotopic xenograft mouse models for human pancreatic cancer

Experimental and Therapeutic Medicine

Volumn 10, Issue 3, 2015, Pages 1033-1038

  Dai, Lei ^a,b   Lu, Caide ^a,b   Yu, Xi ^b   Dai, Long Jun ^c   Zhou, Jeff X ^a  

^a NINGBO UNIVERSITY   (China)

^b Lihui Li Hospital   (China)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Orthotopic tumor model; Pancreatic carcinoma; Xenograft tumor model

Indexed keywords

MATRIGEL; RED FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FLUORESCENCE IMAGING; HISTOLOGY; LAPAROTOMY; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84937712772     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2642     Document Type: Article

References (15)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics 2012. CA Cancer J Clin 62: 10‑29, 2012.
2. Brennan MF: Adjuvant therapy following resection for pancreatic adenocarcinoma. Surg Oncol Clin N Am 13: 555‑566, 2004.
3. Stojadinovic A, Hoos A, Brennan MF and Conlon KC: Randomized clinical trials in pancreatic cancer. Surg Oncol Clin N Am 11: 207‑229, 2002.
4. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in pancreatic cancer. CA Cancer J Clin 63: 318‑348, 2013.
5. Yamamura K, Kasuya H, Sahin TT, Tan G, Hotta Y, Tsurumaru N, Fukuda S, Kanda M, Kobayashi D, Tanaka C, et al: Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. Ann Surg Oncol 21: 691‑698, 2014.
6. Nikfarjam M, Yeo D, He H, Baldwin G, Fifis T, Costa P, Tan B, Yang E, Wen S and Christophi C: Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma. J Invest Surg 26: 352‑359, 2013.
7. Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G and Ciardiello F: The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol 65: 200‑211, 2008.
8. Bimonte S, Barbieri A, Palma G, Luciano A, Rea D and Arra C: Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer. BioMed Res Int 2013: 810423, 2013.
9. Nangami GN, Watson K, Parker Johnson K, Okereke KO, Sakwe A, Thompson P, Frimpong N and Ochieng J: Fetuin‑A (α2HS‑glycoprotein) is a serum chemo‑attractant that also promotes invasion of tumor cells through Matrigel. Biochem Biophys Res Commun 438: 660‑665, 2013.
10. Büchler P, Reber HA, Roth MM, Shiroishi M, Friess H and Hines OJ: Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia 9: 119‑127, 2007.
11. Hakkarainen T, Särkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A and Hemminki A: Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 18: 627‑641 2007.
12. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed‑dose rate infusion) compared with gemcitabine (30‑minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27: 3778‑3785, 2009.
13. McAllister SS and Weinberg RA: Tumor‑host interactions: A far‑reaching relationship. J Clin Oncol 28: 4022‑4028, 2010.
14. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, et al; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC): Randomized phase III trial of gemcitabine plus cisplatin compared with single‑agent gemcitabine as first‑line treatment of patients with advanced pancreatic cancer: The GIP‑1 study. J Clin Oncol 28: 1645‑1651, 2010.
15. Cui L, Chen P, Tan Z, Li W and Dong Z: Hemostatic gelatin sponge is a superior matrix to matrigel for establishment of LNCaP human prostate cancer in nude mice. Prostate 72: 1669‑1677, 2012.